Navidea Biopharmaceuticals
Dublin, United States
9 employees
Post-IPO Equity
Total: $133.75M
Biopharma, Biotechnology +1
General Information
Dublin, United States
BounceWatch is an independent company data service, not affiliated with Navidea Biopharmaceuticals . To contact Navidea Biopharmaceuticals , visit navidea.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
United States Market
Biopharma
About Navidea Biopharmaceuticals
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $2.75M | - |
|
27 Apr 2023 |
| Post IPO Debt | $1.00M | 1 |
John K. Scott
|
05 Jul 2022 |
| Post IPO Debt | $2.50M | - |
|
12 Apr 2022 |
| Post IPO Equity | $5.00M | 1 |
John K. Scott
|
02 Mar 2021 |
| Post IPO Debt | $60.00M | 1 |
|
11 May 2015 |
| Post IPO Debt | $30.00M | 1 |
Oxford Finance LLC
|
06 Mar 2014 |
| Post IPO Equity | $2.50M | - |
|
21 Jan 2014 |
| Post IPO Equity | $30.00M | 1 |
|
14 Sep 2013 |
Navidea Biopharmaceuticals Alternatives & Competitors
Regulating Inflammation - through the nervous system
Crafting next-generation therapies through innovative protein and antibody fusion for enhanced treat...
Lab21 is a rapidly growing healthcare diagnostics business. The company’s vision is of providing per...
FAQ About Navidea Biopharmaceuticals
Source: BounceWatch company record for Navidea Biopharmaceuticals , https://bouncewatch.com/company/navidea-biopharmaceuticals, updated 30 November 2024. When citing, please name BounceWatch and link this page.
